KPG Biopharma

KPG Biopharma is a clinical-stage biopharmaceutical company headquartered in Nanjing, China, dedicated to the discovery and development of innovative small molecule drugs for cancer, autoimmune diseases, and inflammatory conditions. The company's research engine focuses on two primary technological pillars: next-generation Cereblon (CRBN) E3 ligase modulators (CELMoDs) and multi-kinase inhibitors. Its lead asset, KPG-818, is a potent and selective CRBN modulator currently being evaluated in Phase 2 clinical trials for systemic lupus erythematosus and Phase 1 trials for hematologic malignancies. Another key program, KPG-121, is a multi-kinase inhibitor targeting VEGFR2 and MET pathways for the treatment of advanced solid tumors. KPG Biopharma leverages its expertise in medicinal chemistry to address significant unmet medical needs through precise molecular targeting and improved safety profiles.